Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

RVNC has been the subject of a number of other research reports. William Blair reaffirmed a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Barclays reaffirmed an “equal weight” rating and set a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.66.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $3.80 on Tuesday. The stock’s fifty day moving average price is $5.09 and its 200 day moving average price is $4.43. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $9.74. The company has a market cap of $398.62 million, a price-to-earnings ratio of -1.97 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. As a group, equities research analysts anticipate that Revance Therapeutics will post -1.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RVNC. Certuity LLC purchased a new stake in Revance Therapeutics in the 2nd quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Revance Therapeutics during the second quarter worth $33,000. Hsbc Holdings PLC acquired a new stake in Revance Therapeutics during the second quarter valued at $38,000. Nisa Investment Advisors LLC increased its holdings in Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 18,077 shares in the last quarter. Finally, FORA Capital LLC purchased a new position in Revance Therapeutics in the third quarter valued at $54,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.